Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
BioStock: PHIs CEO eyes new business opportunities
BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.
HoloMonitor Fluorescence Now at Novo Nordisk
PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.
Rights Issue 2022
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.
HoloMonitor User Spotlight: Monica Hellesvik
Monica Hellesvik, Ph.D. candidate at University of Bergen, shares how she uses HoloMonitor as her main method to study cancer cell behavior.
Continued Sales Growth for PHI
PHI’s sales in November – January gained 240 % and amounted to 2.7 (0.8) MSEK. Sales over the past four fiscal quarters (Feb 2021 – Jan 2022) amount to 8.8 (2.3) MSEK.
PHI Moves to New Premises
As of today, Phase Holographic Imaging’s registered office is Skiffervägen 48, 224 78 Lund, Sweden.
Switzerland
Austria
The Board of Directors proposes decision on a rights issue of units and a directed issue of convertibles
The Board of Directors of Phase Holographic Imaging has today decided to propose that the Extraordinary General Meeting shall decide on a rights issue, which initially can provide the company with approx. SEK 72.4 million.